Clinical trials: Respiratory Tract Infections
Influenza
Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM
The aim of this study is to evaluate the immune response and the safety of one injection of FluarixTM/ Influsplit SSW® 2010/2011 or Pandemrix TM in subjects who had received a single Pandemrix TM dose at least 6 months preceding…
- Trial name
- NCT01160237
- Testing
- PandemrixTM, FluarixTM/ Influsplit SSW® 2010/2011
- Where
- 5 sites in Germany
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumonia
Performance Study for InferRead CT Pneumonia.AI
A retrospective, blineded, multicenter study of the InferRead CT Pneumonia.AI to evaluate the performance in identifying non-contrast chest CT scans containing pneumonia findings.
- Trial name
- NCT04955704
- Testing
- InferRead CT Pneumonia.AI
- Volunteers
- 423 people, healthy volunteers welcome
- Sponsor
- Infervision
Covid19, Pneumonia, Viral
Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19
Evaluate the safety pharmacokinetics and pharmacodynamics (PK/PD)of a single dose of Kamada anti-severe acute respiratory syndrome (SARS)- CoV-2 in patients hospitalized with COVID-19 caused pneumonia
- Trial name
- NCT04550325
- Testing
- Kamada Anti-SARS-CoV-2
- Where
- 4 sites in Israel
- Volunteers
- 12 people
- Sponsor
- Kamada, Ltd.
Acute Bronchitis
To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis
A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter, Dose-finding, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of ALC-2203 in Patients with Acute Bronchitis
- Trial name
- NCT07061925
- Testing
- ALC-2203-1, ALC-2203-2, ALC-2203-AC
- Where
- South Korea
- Volunteers
- 169 people
- Sponsor
- Korea Arlico Pharm. Co., Ltd
Influenza
Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older
This clinical trial aims to study the immunogenicity of GSK Biologicals' influenza vaccine GSK2186877A in people aged 65 years or older.
- Trial name
- NCT00765076
- Testing
- GSK Biologicals' influenza vaccine GSK2186877A, GSK Biologicals' Fluarix
- Where
- 4 sites in United States, Spain
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19, Coronavirus Disease 2019
LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia
This is a Phase 2, proof of concept, randomized, placebo-controlled, multicenter study to evaluate the ability of LB1148 to attenuate pulmonary dysfunction associated with COVID-19 pneumonia.
- Conditions
- COVID-19, Coronavirus Disease 2019, Covid19, COVID-19 Pneumonia
- Trial name
- NCT04390217
- Testing
- LB1148
- Sponsor
- Leading BioSciences, Inc
Cough
Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 in Chronic Cougher
This study is for therapeutic confirmation of AG1321001 to evaluate the safety and efficacy as an anti-tussive agent in cough patients.
- Trial name
- NCT00380315
- Testing
- AG1321001(drug)
- Where
- South Korea
- Volunteers
- 396 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Influenza
A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine
The pivotal Phase 3 trial plans to enroll a total of approximately 12,460 participants aged 50+ over two years. Participants will be immunized twice with the M-001 universal influenza vaccine candidate or placebo and then…
- Trial name
- NCT03450915
- Testing
- M-001, Saline
- Where
- 2 sites in Poland
- Volunteers
- 12,460 people, healthy volunteers welcome
- Sponsor
- BiondVax Pharmaceuticals ltd.
Influenza
Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.
To compare the groups with respect to influenza immune responses following Dose 1 of Fluzone vaccine (2006-2007 formulation).
- Trial name
- NCT00390884
- Testing
- Influenza Virus Vaccine, Fluzone®
- Where
- 5 sites in United States
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Cough, Upper Respiratory Infection
A Novel Formulation of Pasteurized Maple Cough Syrup Compared With Placebo on Nocturnal Cough and Sleep Quality in Infants With Upper Respiratory Infection
Cough is a frequent symptom in children and infants and is one of the most common reasons parents visit a healthcare provider for their child.
- Conditions
- Cough, Upper Respiratory Infection, Nocturnal Cough
- Trial name
- NCT01588249
- Testing
- Pasteurized maple syrup
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Zarbee's Inc.
Diphtheria, Tetanus
Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan
To assess the immunogenicity profile of ADACEL™, Tetanus and Diphtheria Toxoids Adsorbed combined with Component Pertussis Vaccine (TdcP Vaccine) one month after administration.
- Conditions
- Diphtheria, Tetanus, Pertussis
- Trial name
- NCT00258908
- Testing
- Diphteria, tetanus, and Acellular Pertussis vaccine
- Where
- Taiwan
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza A Virus Infection
Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment
This study aims to evaluate the safety and effect of interferon-alpha lozenges when used in combination with oseltamivir (Tamiflu) to treat influenza.
- Trial name
- NCT01146535
- Testing
- Interferon-alpha, Oseltamivir, maltose
- Where
- 4 sites in Taiwan
- Volunteers
- 40 people
- Sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Respiratory Syncytial Virus Infections+Metapneumovirus
A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults
The aim of this study is to evaluate the safety, reactogenicity, and immune response of the different formulations of the investigational RSV/hMPV combination vaccine and investigational hMPV vaccine in younger and older adults.
- Trial name
- NCT07628049
- Testing
- RSV/hMPV_V low dose vaccine, RSV/hMPV_V medium dose vaccine, RSV/hMPV_V high dose vaccine
- Where
- 5 sites in United States, Australia
- Volunteers
- 1,456 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HCV Infection
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection
The purpose of this study was to investigate the safety, tolerability, pharmacokinetics (PK), and antiviral activity of multiple doses of ACH-0137171 in participants with chronic hepatitis C virus (HCV) infection.
- Trial name
- NCT00401947
- Testing
- ACH-0137171
- Where
- 9 sites in United States, Germany and 1 more
- Volunteers
- 30 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Influenza
Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM
The purpose of this study is to generate additional data on the immunogenicity and safety of revaccination with Fluzone Intradermal (ID) or Fluzone Intramuscular (IM) vaccine.
- Trial name
- NCT01011049
- Testing
- Influenza Virus Vaccine USP Trivalent Types A and B
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Common Cold
To Investigate the Gastrointestinal Behaviour of Two Triple Combination Products in Healthy Male Volunteers
This clinical study will be conducted to characterize the gastrointestinal transit of two multi-symptoms formulations by inclusion of a radiolabel marker.
- Trial name
- NCT03415243
- Testing
- Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg, Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acute Bronchitis
Clinical Trial to Evaluate the Efficacy and Safety of YHP2401 Compared to YHR2402 and YHR2403 for Acute Bronchitis
A Multicenter, Randomized, Double-blind, Parallel, Active-controlled, Superiority, Phase III Clinical Trial to Evaluate the Efficacy and Safety of YHP2401 Compared to YHR2402 and YHR2403 for Acute Bronchitis
- Trial name
- NCT07111468
- Testing
- YHP2401, YHR2402, YHR2403
- Where
- 11 sites in South Korea
- Volunteers
- 286 people
- Sponsor
- Yuhan Corporation
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Influenza
Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age
The purpose of this study is to evaluate Immunogenicity and Safety of a High-Dose (HD) Influenza Vaccine (IV) in Adults 50 through 64 Years of Age.
- Trial name
- NCT06641180
- Testing
- High-Dose trivalent influenza vaccine (Split virion, Inactivated), Standard-dose trivalent influenza vaccine (Split virion, Inactivated)
- Where
- 20 sites in United States
- Volunteers
- 1,180 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Respiratory Syncytial Virus Infections
A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV
The purpose of the study is to learn about the safety and amount of sisunatovir in the blood of infants and children up to age 60 months.
- Trial name
- NCT06102174
- Testing
- Active
- Where
- 9 sites in United States, Japan and 1 more
- Volunteers
- 10 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.